ProMIS Neurosciences Inc
F:23J
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
ProMIS Neurosciences Inc
F:23J
|
CA |
|
S
|
Scatec ASA
SWB:66T
|
NO |
|
C
|
CBRE Group Inc
DUS:RF6
|
US |
|
Kering SA
F:PPXB
|
FR |
|
E
|
EforA Energy Ltd
JSE:EEL
|
ZA |
|
Siauliu Bankas AB
F:ZH5
|
LT |
|
L
|
Lantheus Holdings Inc
F:0L8
|
US |
|
W
|
WiseTech Global Ltd
F:17W
|
AU |
|
H
|
Huadian Energy Co Ltd
SSE:900937
|
CN |
|
R
|
Richter Gedeon Vegyeszeti Gyar Nyrt
BET:RICHT
|
HU |
|
B
|
BlackRock Inc
XETRA:UU2
|
US |
|
H
|
Hummingbird Resources PLC
SWB:2HM
|
UK |
|
Eli Lilly and Co
NYSE:LLY
|
US |
|
S
|
SoftBank Group Corp
XHAM:SFT
|
JP |
|
G
|
Gran Tierra Energy Inc
F:G1P
|
CA |
|
BYD Co Ltd
SZSE:002594
|
CN |
|
T
|
TravelSky Technology Ltd
XMUN:TVL
|
CN |
|
AstraZeneca PLC
LSE:AZN
|
UK |
|
Catana Group SA
PAR:CATG
|
FR |
|
V
|
Vita 34 AG
XBER:V3V
|
DE |
ProMIS Neurosciences Inc
ProMIS Neurosciences Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 5 full-time employees. The company went IPO on 2005-09-30. ProMIS Neurosciences, Inc. is a Canada-based development-stage biotechnology company. The firm is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The firm is focused on the discovery engine, which is based on the use of two complementary algorithms: ProMIS and Collective Coordinates, which are used to predict targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. The firm is focused on developing antibody therapeutics for AD, ALS and PD. The firm has a wholly owned subsidiary is ProMIS Neurosciences (US) Inc. (ProMIS USA).
ProMIS Neurosciences Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 5 full-time employees. The company went IPO on 2005-09-30. ProMIS Neurosciences, Inc. is a Canada-based development-stage biotechnology company. The firm is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The firm is focused on the discovery engine, which is based on the use of two complementary algorithms: ProMIS and Collective Coordinates, which are used to predict targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. The firm is focused on developing antibody therapeutics for AD, ALS and PD. The firm has a wholly owned subsidiary is ProMIS Neurosciences (US) Inc. (ProMIS USA).
